Whalesbook
Sun Pharma ne Organon ko kyun kharida?
Dekho bhaiyo, Sun Pharma ne pakka plan bana liya hai duniya bhar mein apna business failane ka! Unhone Organon & Co. ko seedha $11.75 Billion mein kharidne ka deal kiya hai, yeh all-cash deal hai jismein Organon shareholders ko per share $14 milenge. Is deal se Sun Pharma ekdum se top-tier global pharma company ban jayegi, jinki combined revenues $12.4 billion ho jayegi aur women's health mein top-three position aa jayegi. Isse unki biosimilars business mein bhi taqat badhegi aur woh duniya bhar mein 150+ countries mein apna saman bech paayenge.
Paisa kahan se aayega aur kitna debt?
Ab itne bade deal ke liye paisa toh lagana padega! Sun Pharma apne cash reserves use karegi aur saath mein $9.25 billion se lekar $9.75 billion tak ka loan bhi legi. Socho zara, Organon pehle se hi $8.6 billion ke debt mein thi (2025 projection ke hisab se). Ab dono milkar kaafi heavy lenders ban jayenge. Haan, company ko umeed hai ki 2 se 4 saal mein $350 million ki savings (synergies) nikal lenge, par manage toh karna hi padega.
Organon ke paas kya hai aur kya problems?
Organon, jo Merck & Co. se 2021 mein alag hui thi, uske paas 70 se zyada products hain, mainly women's health ke. Biosimilars se unki 7% revenue aati thi (2025 mein). 2025 mein Organon ki revenue $6.2 billion thi. Lekin, Organon kaafi time se thoda struggle kar rahi hai. 2025 mein unki revenue 3% gir gayi thi aur profit bhi kam ho raha tha. Upar se, unke financial controls mein bhi dikkatein aayi hain, aur woh CEO bhi khoj rahe hain. Toh Sun Pharma ko yeh sab bhi sambhalna hoga.
Market kya keh raha hai?
Indian pharma sector abhi 7-9% ke growth rate se chal raha hai FY2026 mein. Sun Pharma ka P/E ratio 35-38x hai, industry average 33x ke aas paas hai. Unki market cap ₹4.2 trillion se zyada hai. Yeh sab dikhata hai ki investors un par bharosa karte hain, par ab yeh naya debt unke future earnings ko thoda pressure mein dal sakta hai.
Sabse Bade Risks?
Sabse badi tension toh yeh bada debt hai. Organon pehle se $8.6 billion debt mein thi, aur ab Sun Pharma aur paisa udhaar le rahi hai. Isse future mein R&D ya dusre investments mein dikkat aa sakti hai. Aur Organon kaafi time se revenue aur profit drop face kar rahi hai, toh usko theek karna, margin badhana, aur Nexplanon jaise products ko competition mein lana bhi ek challenge hoga. Dono companies ko achhe se mix karna aur Organon ki purani problems ko solve karna Sun Pharma ke liye aasan nahi hoga.
Analyst Views?
Bade bade analysts is deal ko positive hi dekh rahe hain. Zyadatar 'Buy' rating de rahe hain aur price targets bhi badha rahe hain. Jaise ICICI Securities ne 'Buy' rating rakhi hai aur target INR 2,000 diya hai. JM Financial aur Emkay Global ne toh ₹2,320 tak ke targets diye hain. Woh deal se hone wali synergies aur EPS growth par focus kar rahe hain. Ab dekhte hain Sun Pharma Organon ko kitna achhe se integrate kar paati hai aur growth dikhati hai.